Download PDF

1. Company Snapshot

1.a. Company Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.The company operates through two segments, Innovative Medicines and Sandoz.The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.


It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives.It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services.


Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc.to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma.The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Show Full description

1.b. Last Insights on NOVN

Novartis' recent momentum is driven by its robust pipeline, regulatory approvals, and strategic investments. The company's construction of a new AI-focused research center in San Diego underscores its commitment to innovation and pipeline expansion. Additionally, Novartis' 29-year dividend growth streak, with a recently announced increase, demonstrates its dedication to shareholder returns.

1.c. Company Highlights

2. Novartis' Q4 2025 Earnings: A Strong Finish to a Growth-Focused Year

Novartis reported a core operating income of $17.6 billion, with a record core margin of 40.1%, exceeding its 40% goal two years ahead of plan. The company's EPS came in at $1.58, beating analyst estimates of $1.55. Revenue growth was 8% for the full year, driven by key growth brands such as Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio. The company's strong financial performance was highlighted by Harry Kirsch, the outgoing CFO, who noted that Novartis had achieved its midterm core margin target two years early.

Publication Date: Feb -05

📋 Highlights
  • Full-Year Financial Outperformance:: Achieved 8% sales growth ($4.8B from Kisqali, $4.4B from Kesimpta) and 14% core operating income growth, with a 40.1% core margin exceeding 40% target two years early.
  • Pipeline Momentum:: 7 pivotal readouts in 2025, including remibrutinib’s FDA submission, pelabresib’s Phase III myelofibrosis data, and Zolgensma’s $1B+ gene therapy potential (7,500+ patients treated globally).
  • High-Growth Brands:: Kisqali (57% growth), Scemblix (85% growth), Pluvicto (42%, $2B), and Leqvio (57% growth) drove performance, with Kisqali’s franchise extending beyond 2030 via CDK2/4 programs.
  • 2026 Strategic Outlook:: Projects low single-digit sales growth, $17.6B free cash flow, and a CHF 3.70 dividend (6% increase), despite Avidity’s 1-2% margin dilution and patent expiry challenges.

Financial Performance

The company's financial performance was robust, with a free cash flow of $17.6 billion and a dividend proposal of CHF 3.70 per share, a 6% increase. For 2026, Novartis expects low single-digit sales growth and low single-digit core operating income decline due to the Avidity deal. The company's valuation metrics indicate a reasonable price, with a P/E Ratio of 20.66, P/B Ratio of 6.71, and a Dividend Yield of 2.95%. The EV/EBITDA ratio is 13.8, suggesting a relatively moderate valuation.

Pipeline Progress

Novartis has a strong pipeline, with highlights including remibrutinib's FDA submission for chronic inducible urticaria and a path forward for pelabresib in the EU and US. The company's renal portfolio is progressing steadily, with IgAN and C3G contributing to growth. Novartis is also enthusiastic about its cell therapy programs, including YTB, which is currently in pivotal studies for four indications. The company's CEO, Vasant Narasimhan, noted that Novartis is optimistic about its food allergy treatment, seeing it as a multibillion-dollar opportunity.

Growth Prospects

The company is confident in its 5-6% sales CAGR through 2030, driven by priority brands and pipeline assets. Mukul Mehta, the incoming CFO, expects a strong second half of 2026, with sales growing mid-single digits and core operating income growing mid- to high single digits. Analysts estimate next year's revenue growth at 5.1%, indicating a relatively stable outlook. With a strong track record of execution and a focus on productivity, financial discipline, and operational excellence, Novartis is well-positioned for continued growth.

Valuation and Return Metrics

The company's return on equity (ROE) is 34.12%, indicating a strong ability to generate returns for shareholders. The return on invested capital (ROIC) is 18.51%, suggesting efficient use of capital. With a net debt to EBITDA ratio of 0.98, Novartis has a relatively manageable debt burden. Overall, the company's valuation metrics and return metrics suggest a reasonable price and a strong ability to generate returns.

3. NewsRoom

Card image cap

Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics

Mar -02

Source:

Card image cap

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory

Feb -28

Source:

Card image cap

Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas

Feb -28

Source:

Card image cap

Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger

Feb -27

Source:

Card image cap

Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug

Feb -27

Source:

Card image cap

Sector Update: Health Care Stocks Advance Late Afternoon

Feb -27

Source:

Card image cap

European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises

Feb -27

Source:

Card image cap

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Feb -27

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (1.90%)

6. Segments

Innovative Medicines

Expected Growth: 2.2%

The segment is expected to grow due to the strong performance of its key brands, including Entresto and Cosentyx, which have shown significant sales growth. Additionally, Novartis' robust pipeline of new medicines and increasing demand for its products in emerging markets will contribute to growth.

7. Detailed Products

Cosentyx

A prescription medicine used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and moderate to severe Crohn's disease.

Gilenya

A prescription medicine used to treat relapsing forms of multiple sclerosis (MS) in adults.

Tasigna

A prescription medicine used to treat certain types of leukemia, including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

Kisqali

A prescription medicine used to treat certain types of breast cancer, including HR+/HER2- advanced or metastatic breast cancer.

Entresto

A prescription medicine used to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

Xolair

A prescription medicine used to treat moderate to severe asthma in people 12 years and older whose asthma is not well-controlled with inhaled corticosteroids.

Lucentis

A prescription medicine used to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

Alcon Contact Lenses

A range of contact lenses designed for comfort, convenience, and clear vision.

Sandoz Biosimilars

A range of biosimilar medicines used to treat various conditions, including cancer, autoimmune diseases, and inflammatory diseases.

8. Novartis AG's Porter Forces

Forces Ranking

Threat Of Substitutes

Novartis AG faces moderate threat from substitutes due to the presence of alternative treatments and generics in the pharmaceutical industry.

Bargaining Power Of Customers

Novartis AG has a diverse customer base, including patients, healthcare providers, and payers, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

Novartis AG relies on a network of suppliers for raw materials, manufacturing, and logistics, but has some bargaining power due to its large scale and diversified supply chain.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant R&D investments, regulatory hurdles, and patent protections, which limits the threat of new entrants for Novartis AG.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players, including Pfizer, Roche, and Merck, which increases the intensity of rivalry for Novartis AG.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 36.09%
Debt Cost 3.95%
Equity Weight 63.91%
Equity Cost 6.28%
WACC 5.44%
Leverage 56.46%

11. Quality Control: Novartis AG passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Novartis

A-Score: 6.5/10

Value: 3.0

Growth: 4.2

Quality: 8.3

Yield: 7.5

Momentum: 6.5

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
GSK

A-Score: 6.3/10

Value: 4.7

Growth: 2.2

Quality: 7.1

Yield: 6.9

Momentum: 9.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Sanofi

A-Score: 5.9/10

Value: 6.2

Growth: 4.0

Quality: 8.0

Yield: 7.5

Momentum: 2.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
AstraZeneca

A-Score: 5.9/10

Value: 1.3

Growth: 7.6

Quality: 6.8

Yield: 3.1

Momentum: 9.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Roche

A-Score: 5.4/10

Value: 1.1

Growth: 3.0

Quality: 6.4

Yield: 5.6

Momentum: 8.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Bayer

A-Score: 4.4/10

Value: 7.0

Growth: 2.1

Quality: 2.7

Yield: 3.1

Momentum: 8.5

Volatility: 3.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

129.96$

Current Price

129.96$

Potential

-0.00%

Expected Cash-Flows